TIGIT
T-cell immunoreceptor with Ig and ITIM domains
As of the edition of 20 October 2026, TIGIT (T-cell immunoreceptor with Ig and ITIM domains, UniProt Q495A1) has 11 drugs tested at it and 18 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q495A1
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 12
- Disease areas
- Cancer; Lungs and airways; Digestive system; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Immune system
- Registered trials of its drugs
- 139
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Stopped | 3 |
| Status not established | 4 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tiragolumab | Active | Phase 3 | none listed |
| Domvanalimab | Active | Phase 3 | none listed |
| Ociperlimab | Stopped | Phase 3 | none listed |
| Vibostolimab | Active | Phase 3 | none listed |
| Belrestotug | Active | Phase 3 | none listed |
| Renvistobart | Stopped | Phase 2 | none listed |
| ASP-8374 | Status not established | Phase 1 | none listed |
| Etigilimab | Stopped | Phase 2 | none listed |
| IBI-939 | Status not established | Phase 1 | none listed |
| IBI321 | Status not established | Phase 1 | none listed |
| HLX301 | Status not established | Phase 2 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Engaged | 9 |
| Undetermined | 3 |
| Total on the list | 18 |
| Company | Route |
|---|---|
| Novartis | Route A |
| BeiGene | Route A |
| Bristol Myers Squibb | Route A |
The other 15 companies at TIGIT
In the product18 companies in all; 15 are not named here, and no score is.
See the 18 companies at TIGIT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.